Andrew Derodra Acquires 142 Shares of Vectura Group PLC (VEC) Stock
Vectura Group PLC (LON:VEC) insider Andrew Derodra acquired 142 shares of the business’s stock in a transaction on Friday, October 6th. The stock was acquired at an average price of GBX 106 ($1.39) per share, with a total value of £150.52 ($197.90).
Andrew Derodra also recently made the following trade(s):
- On Friday, September 8th, Andrew Derodra purchased 158 shares of Vectura Group PLC stock. The shares were purchased at an average price of GBX 94 ($1.24) per share, with a total value of £148.52 ($195.27).
- On Thursday, September 7th, Andrew Derodra purchased 82,000 shares of Vectura Group PLC stock. The shares were purchased at an average price of GBX 90 ($1.18) per share, with a total value of £73,800 ($97,028.66).
- On Friday, August 4th, Andrew Derodra purchased 135 shares of Vectura Group PLC stock. The shares were purchased at an average price of GBX 111 ($1.46) per share, with a total value of £149.85 ($197.02).
Vectura Group PLC (LON VEC) opened at 102.00 on Thursday. Vectura Group PLC has a 52-week low of GBX 88.90 and a 52-week high of GBX 166.97. The stock’s market cap is GBX 692.07 million. The company’s 50 day moving average is GBX 104.56 and its 200-day moving average is GBX 119.67.
TRADEMARK VIOLATION NOTICE: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/10/12/andrew-derodra-acquires-142-shares-of-vectura-group-plc-vec-stock.html.
A number of brokerages have recently issued reports on VEC. Numis Securities Ltd restated a “buy” rating and set a GBX 205 ($2.70) price target on shares of Vectura Group PLC in a report on Thursday, October 5th. J P Morgan Chase & Co cut their price target on shares of Vectura Group PLC from GBX 210 ($2.76) to GBX 180 ($2.37) and set an “overweight” rating for the company in a report on Thursday, September 21st. Citigroup Inc. cut their price target on shares of Vectura Group PLC from GBX 200 ($2.63) to GBX 180 ($2.37) and set a “buy” rating for the company in a report on Monday, September 18th. Peel Hunt restated a “hold” rating and set a GBX 160 ($2.10) price target on shares of Vectura Group PLC in a report on Wednesday, September 6th. Finally, Panmure Gordon restated a “buy” rating on shares of Vectura Group PLC in a report on Wednesday, August 30th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of GBX 199.63 ($2.62).
Vectura Group PLC Company Profile
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Stock Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related stocks with our FREE daily email newsletter.